Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company was founded on May 25, 2020 and is headquartered in New Hope, PA.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of OBIO is 5.93 USD — it has decreased by −5.50% in the past 24 hours. Watch Orchestra BioMed Holdings, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Orchestra BioMed Holdings, Inc. stocks are traded under the ticker OBIO.
OBIO stock has risen by 5.62% compared to the previous week, the month change is a 19.25% rise, over the last year Orchestra BioMed Holdings, Inc. has showed a 15.37% increase.
We've gathered analysts' opinions on Orchestra BioMed Holdings, Inc. future price: according to them, OBIO price has a max estimate of 20.00 USD and a min estimate of 14.00 USD. Watch OBIO chart and read a more detailed Orchestra BioMed Holdings, Inc. stock forecast: see what analysts think of Orchestra BioMed Holdings, Inc. and suggest that you do with its stocks.
OBIO reached its all-time high on Apr 3, 2023 with the price of 23.39 USD, and its all-time low was 4.22 USD and was reached on Apr 25, 2024. View more price dynamics on OBIO chart. See other stocks reaching their highest and lowest prices.
OBIO stock is 7.24% volatile and has beta coefficient of 2.41. Track Orchestra BioMed Holdings, Inc. stock price on the chart and check out the list of the most volatile stocks — is Orchestra BioMed Holdings, Inc. there?
Today Orchestra BioMed Holdings, Inc. has the market capitalization of 227.33 M, it has decreased by −3.20% over the last week.
Orchestra BioMed Holdings, Inc. is going to release the next earnings report on Nov 11, 2024. Keep track of upcoming events with our Earnings Calendar.
OBIO earnings for the last quarter are −0.45 USD per share, whereas the estimation was −0.39 USD resulting in a −14.65% surprise. The estimated earnings for the next quarter are −0.43 USD per share. See more details about Orchestra BioMed Holdings, Inc. earnings.
Orchestra BioMed Holdings, Inc. revenue for the last quarter amounts to 778.00 K USD, despite the estimated figure of 850.00 K USD. In the next quarter, revenue is expected to reach 703.25 K USD.
OBIO net income for the last quarter is −15.98 M USD, while the quarter before that showed −13.46 M USD of net income which accounts for −18.70% change. Track more Orchestra BioMed Holdings, Inc. financial stats to get the full picture.
No, OBIO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2024, the company has 56.00 employees. See our rating of the largest employees — is Orchestra BioMed Holdings, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Orchestra BioMed Holdings, Inc. EBITDA is −58.00 M USD, and current EBITDA margin is −1.86 K%. See more stats in Orchestra BioMed Holdings, Inc. financial statements.
Like other stocks, OBIO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Orchestra BioMed Holdings, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Orchestra BioMed Holdings, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Orchestra BioMed Holdings, Inc. stock shows the sell signal. See more of Orchestra BioMed Holdings, Inc. technicals for a more comprehensive analysis. If you're still not sure, try looking for inspiration in our curated watchlists.